170 related articles for article (PubMed ID: 19457483)
1. Where are we with probucol: a new life for an old drug?
Yamashita S; Matsuzawa Y
Atherosclerosis; 2009 Nov; 207(1):16-23. PubMed ID: 19457483
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of anti-atherogenic action of probucol].
Ohya T; Egusa G
Nihon Rinsho; 1999 Dec; 57(12):2831-6. PubMed ID: 10638221
[TBL] [Abstract][Full Text] [Related]
3. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
Inagaki M; Nakagawa-Toyama Y; Nishida M; Nakatani K; Nakaoka H; Kawase M; Kawase R; Tsubakio-Yamamoto K; Masuda D; Ohama T; Matsuyama A; Ishigami M; Komuro I; Yamashita S
J Atheroscler Thromb; 2012; 19(7):643-56. PubMed ID: 22785024
[TBL] [Abstract][Full Text] [Related]
4. Did we abandon probucol too soon?
Yamashita S; Masuda D; Matsuzawa Y
Curr Opin Lipidol; 2015 Aug; 26(4):304-16. PubMed ID: 26125504
[TBL] [Abstract][Full Text] [Related]
5. [Probucol treatment of hyperlipidemia].
Koizumi J
Nihon Rinsho; 1994 Dec; 52(12):3279-84. PubMed ID: 7853723
[TBL] [Abstract][Full Text] [Related]
6. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.
Yamashita S; Bujo H; Arai H; Harada-Shiba M; Matsui S; Fukushima M; Saito Y; Kita T; Matsuzawa Y
J Atheroscler Thromb; 2008 Dec; 15(6):292-303. PubMed ID: 19060422
[TBL] [Abstract][Full Text] [Related]
7. [Coronary artery bypass graft in adolescent suffering from homozygous familial hypercholesterolemia resistant to probucol therapy].
Ayegnon KG; Morcos KK; Yangni-Angate KH; Ahmed-Nasr M
Mali Med; 2009; 24(2):62-4. PubMed ID: 19666374
[TBL] [Abstract][Full Text] [Related]
8. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
Kajinami K; Nishitsuji M; Takeda Y; Shimizu M; Koizumi J; Mabuchi H
Atherosclerosis; 1996 Feb; 120(1-2):181-7. PubMed ID: 8645359
[TBL] [Abstract][Full Text] [Related]
9. Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.
Hong SC; Zhao SP; Wu ZH
Int J Cardiol; 2007 Jan; 115(1):29-35. PubMed ID: 16766063
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
11. Viability of developing CETP inhibitors.
Sirtori CR; Mombelli G
Cardiovasc Ther; 2008; 26(2):135-46. PubMed ID: 18485135
[TBL] [Abstract][Full Text] [Related]
12. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Buckley MM; Goa KL; Price AH; Brogden RN
Drugs; 1989 Jun; 37(6):761-800. PubMed ID: 2667936
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
Mao SJ; Yates MT; Rechtin AE; Jackson RL; Van Sickle WA
J Med Chem; 1991 Jan; 34(1):298-302. PubMed ID: 1992130
[TBL] [Abstract][Full Text] [Related]
14. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
Artery; 1993; 20(1):1-18. PubMed ID: 8447724
[TBL] [Abstract][Full Text] [Related]
15. [The effects of probucol in man (author's transl)].
Leutenegger M
Nouv Presse Med; 1980 Oct; 9(40):2985-9. PubMed ID: 7443436
[TBL] [Abstract][Full Text] [Related]
16. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.
Tanous D; Hime N; Stocker R
Redox Rep; 2008; 13(2):48-59. PubMed ID: 18339247
[TBL] [Abstract][Full Text] [Related]
17. Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia.
Moreira EL; Aguiar AS; de Carvalho CR; Santos DB; de Oliveira J; de Bem AF; Xikota JC; Walz R; Farina M; Prediger RD
Neurosci Lett; 2013 Apr; 541():193-8. PubMed ID: 23470631
[TBL] [Abstract][Full Text] [Related]
18. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Davidson M
Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
[TBL] [Abstract][Full Text] [Related]
20. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
